Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1989 Jul;57(7):2237–2245. doi: 10.1128/iai.57.7.2237-2245.1989

Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.

W A Flegel 1, A Wölpl 1, D N Männel 1, H Northoff 1
PMCID: PMC313866  PMID: 2731990

Abstract

Toxicity of lipopolysaccharide (LPS) (endotoxin) is, to a large extent, mediated by the activation of monocytes/macrophages and subsequent release of monokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha). It is known that LPS binds readily to serum lipoproteins and that LPS-lipoprotein complexes are less toxic than unbound LPS. Here we present data analyzing the impact of the LPS-serum interaction at the cellular level. By measuring IL-1 TNF-alpha, and IL-6, the interaction of different LPSs or lipid A with human serum could be shown to prevent the activation of human monocytes. The amounts of LPS inactivated by normal human serum did not exceed 10 ng/ml. The LPS-inactivating capacity of serum was shown to be a function of the lipoproteins. Other serum components, such as naturally occurring anti-LPS immunoglobulin G, complement, or nutritive lipids, had no significant influence in our system. Our experiments suggest that serum lipoproteins control endotoxin-induced monocyte activation and monokine release.

Full text

PDF
2237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdelnoor A. M., Harvie N. R., Johnson A. G. Neutralization of bacteria- and endotoxin-induced hypotension by lipoprotein-free human serum. Infect Immun. 1982 Oct;38(1):157–161. doi: 10.1128/iai.38.1.157-161.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abdelnoor A. M., Johnson A. G., Anderson-Imbert A., Nowotny A. Immunization against bacteria- and endotoxin-induced hypotension. Infect Immun. 1981 Jun;32(3):1093–1099. doi: 10.1128/iai.32.3.1093-1099.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arend W. P., Massoni R. J., Niemann M. A., Giclas P. C. Absence of induction of IL-1 production in human monocytes by complement fragments. J Immunol. 1989 Jan 1;142(1):173–178. [PubMed] [Google Scholar]
  4. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  5. Cabana V. G., Siegel J. N., Sabesin S. M. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989 Jan;30(1):39–49. [PubMed] [Google Scholar]
  6. Cavaillon J. M., Haeffner-Cavaillon N. The role of serum in interleukin 1 production by human monocytes activated by endotoxins and their polysaccharide moieties. Immunol Lett. 1985;10(1):35–41. doi: 10.1016/0165-2478(85)90047-1. [DOI] [PubMed] [Google Scholar]
  7. Cham B. E., Knowles B. R. A solvent system for delipidation of plasma or serum without protein precipitation. J Lipid Res. 1976 Mar;17(2):176–181. [PubMed] [Google Scholar]
  8. Freudenberg M. A., Bøg-Hansen T. C., Back U., Galanos C. Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. Infect Immun. 1980 May;28(2):373–380. doi: 10.1128/iai.28.2.373-380.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Freudenberg M. A., Keppler D., Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun. 1986 Mar;51(3):891–895. doi: 10.1128/iai.51.3.891-895.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gaffin S. L., Badsha N., Brock-Utne J. G., Vorster B. J., Conradie J. D. An ELISA procedure for detecting human anti-endotoxin antibodies in serum. Ann Clin Biochem. 1982 May;19(3):191–194. doi: 10.1177/000456328201900313. [DOI] [PubMed] [Google Scholar]
  11. Gallin J. I., Kaye D., O'Leary W. M. Serum lipids in infection. N Engl J Med. 1969 Nov 13;281(20):1081–1086. doi: 10.1056/NEJM196911132812001. [DOI] [PubMed] [Google Scholar]
  12. Gauldie J., Richards C., Harnish D., Lansdorp P., Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251–7255. doi: 10.1073/pnas.84.20.7251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Geiger T., Andus T., Bauer J., Northoff H., Ganter U., Hirano T., Kishimoto T., Heinrich P. C. Cell-free-synthesized interleukin-6 (BSF-2/IFN-beta 2) exhibits hepatocyte-stimulating activity. Eur J Biochem. 1988 Jul 15;175(1):181–186. doi: 10.1111/j.1432-1033.1988.tb14181.x. [DOI] [PubMed] [Google Scholar]
  14. Hoffman J. S., Benditt E. P. Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractions. J Biol Chem. 1982 Sep 10;257(17):10510–10517. [PubMed] [Google Scholar]
  15. Johnson K. J., Ward P. A., Goralnick S., Osborn M. J. Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol. 1977 Sep;88(3):559–574. [PMC free article] [PubMed] [Google Scholar]
  16. Kerttula Y., Vaara M., Pyhälä L. Effect of bacterial lipopolysaccharide on serum high density lipoprotein cholesterol in rabbits. Atherosclerosis. 1984 Jul;52(1):123–126. doi: 10.1016/0021-9150(84)90161-8. [DOI] [PubMed] [Google Scholar]
  17. Kist A., Ho A. D., Räth U., Wiedenmann B., Bauer A., Schlick E., Kirchner H., Männel D. N. Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood. 1988 Jul;72(1):344–348. [PubMed] [Google Scholar]
  18. Lehmann V., Freudenberg M. A., Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med. 1987 Mar 1;165(3):657–663. doi: 10.1084/jem.165.3.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979 Nov;123(5):2133–2143. [PubMed] [Google Scholar]
  20. Mathison J. C., Wolfson E., Ulevitch R. J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988 Jun;81(6):1925–1937. doi: 10.1172/JCI113540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Munford R. S., Dietschy J. M. Effects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis. 1985 Jul;152(1):177–184. doi: 10.1093/infdis/152.1.177. [DOI] [PubMed] [Google Scholar]
  22. Munford R. S., Hall C. L. Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. Science. 1986 Oct 10;234(4773):203–205. doi: 10.1126/science.3529396. [DOI] [PubMed] [Google Scholar]
  23. Munford R. S., Hall C. L., Lipton J. M., Dietschy J. M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest. 1982 Oct;70(4):877–888. doi: 10.1172/JCI110684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Männel D. N., Falk W., Northoff H. Endotoxic activities of tumor necrosis factor independent of IL1 secretion by macrophages/monocytes. Lymphokine Res. 1987 Summer;6(3):151–159. [PubMed] [Google Scholar]
  25. Navab M., Hough G. P., Van Lenten B. J., Berliner J. A., Fogelman A. M. Low density lipoproteins transfer bacterial lipopolysaccharides across endothelial monolayers in a biologically active form. J Clin Invest. 1988 Feb;81(2):601–605. doi: 10.1172/JCI113359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Northoff H., Carter C., Oppenheim J. J. Inhibition of concanavalin A-induced human lymphocyte mitogenic factor (Interleukin-2) production by suppressor T lymphocytes. J Immunol. 1980 Oct;125(4):1823–1828. [PubMed] [Google Scholar]
  27. Northoff H., Glück D., Wölpl A., Kubanek B., Galanos C. Lipopolysaccharide-induced elaboration of interleukin 1 by human monocytes: use for detection of lipopolysaccharide in serum and the influence of serum-lipopolysaccharide interactions. Rev Infect Dis. 1987 Sep-Oct;9 (Suppl 5):S599–S601. doi: 10.1093/clinids/9.supplement_5.s599. [DOI] [PubMed] [Google Scholar]
  28. Obayashi T., Tamura H., Tanaka S., Ohki M., Takahashi S., Kawai T. Endotoxin-inactivating activity in normal and pathological human blood samples. Infect Immun. 1986 Aug;53(2):294–297. doi: 10.1128/iai.53.2.294-297.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Okusawa S., Gelfand J. A., Ikejima T., Connolly R. J., Dinarello C. A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988 Apr;81(4):1162–1172. doi: 10.1172/JCI113431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. RALL D. P., GASKINS J. R., KELLY M. G. Reduction of febrile response to bacterial polysaccharide following incubation with serum. Am J Physiol. 1957 Mar;188(3):559–562. doi: 10.1152/ajplegacy.1957.188.3.559. [DOI] [PubMed] [Google Scholar]
  31. RUDBACH J. A., JOHNSON A. G. RESTORATION OF ENDOTOXIN ACTIVITY FOLLOWING ALTERATION BY PLASMA. Nature. 1964 May 23;202:811–812. doi: 10.1038/202811a0. [DOI] [PubMed] [Google Scholar]
  32. Skarnes R. C. Host defense against bacterial endotoxemia: mechanism in normal animals. J Exp Med. 1970 Aug 1;132(2):300–316. doi: 10.1084/jem.132.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Skarnes R. C. In vivo interaction of endotoxin with a plasma lipoprotein having esterase activity. J Bacteriol. 1968 Jun;95(6):2031–2034. doi: 10.1128/jb.95.6.2031-2034.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tobias P. S., Soldau K., Ulevitch R. J. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986 Sep 1;164(3):777–793. doi: 10.1084/jem.164.3.777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  36. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  37. Ulevitch R. J., Johnston A. R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest. 1978 Dec;62(6):1313–1324. doi: 10.1172/JCI109252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ulevitch R. J., Johnston A. R., Weinstein D. B. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest. 1979 Nov;64(5):1516–1524. doi: 10.1172/JCI109610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Van Lenten B. J., Fogelman A. M., Haberland M. E., Edwards P. A. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2704–2708. doi: 10.1073/pnas.83.8.2704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Von Eschen K. B., Rudbach J. A. Inactivation of endotoxin by serum: a phylogenetic study. J Infect Dis. 1974 Jan;129(1):21–27. doi: 10.1093/infdis/129.1.21. [DOI] [PubMed] [Google Scholar]
  41. Warren H. S., Knights C. V., Siber G. R. Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum. J Infect Dis. 1986 Nov;154(5):784–791. doi: 10.1093/infdis/154.5.784. [DOI] [PubMed] [Google Scholar]
  42. Warren H. S., Novitsky T. J., Ketchum P. A., Roslansky P. F., Kania S., Siber G. R. Neutralization of bacterial lipopolysaccharides by human plasma. J Clin Microbiol. 1985 Oct;22(4):590–595. doi: 10.1128/jcm.22.4.590-595.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Warren H. S., Riveau G. R., de Deckker F. A., Chedid L. A. Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor. Infect Immun. 1988 Jan;56(1):204–212. doi: 10.1128/iai.56.1.204-212.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. YOSHIOKA M., JOHNSON A. G. Characteristics of endotoxin altering fractions derived from normal human serum. J Immunol. 1962 Sep;89:326–335. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES